Johnson & Johnson (JNJ) Deferred Taxes (2009 - 2026)
Johnson & Johnson (JNJ) posted Deferred Taxes of $159.0 million for Q1 2026, up 104.32% sequentially from -$3.7 billion in Q4 2025, and down 92.68% YoY from $2.2 billion in Q1 2025.
Johnson & Johnson (JNJ) Deferred Taxes (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Deferred Taxes data on file, last reported at $159.0 million in Q1 2026.
- Quarterly Deferred Taxes fell 92.68% year-over-year to $159.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$475.0 million (down 130.63% YoY) and the FY2025 annual result came in at $1.5 billion, up 170.45% from the prior year.
- Deferred Taxes improved to $159.0 million in Q1 2026 per JNJ's latest filing, from -$3.7 billion in the prior quarter.
- The five-year high for Deferred Taxes was $2.2 billion in Q3 2025, with the low at -$3.7 billion in Q4 2025.
- Average Deferred Taxes over 5 years is -$313.7 million, with a median of -$16.0 million recorded in 2024.
- The widest YoY moves for Deferred Taxes: up 2364.44% in 2025, down 22881.25% in 2025.
- Johnson & Johnson's Deferred Taxes stood at -$926.0 million in 2022, then slumped by 160.48% to -$2.4 billion in 2023, then jumped by 99.34% to -$16.0 million in 2024, then tumbled by 22881.25% to -$3.7 billion in 2025, then jumped by 104.32% to $159.0 million in 2026.
- Business Quant data shows JNJ's Deferred Taxes at $159.0 million in Q1 2026, -$3.7 billion in Q4 2025, and $2.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 1.48 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 159.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 137.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 159.00 Mn |
| Dec 28, 2025 | -3.68 Bn |
| Sep 28, 2025 | 2.22 Bn |
| Jun 29, 2025 | 825.00 Mn |
| Mar 30, 2025 | 2.17 Bn |
| Dec 29, 2024 | -16.00 Mn |
| Sep 29, 2024 | 90.00 Mn |
| Jun 30, 2024 | -695.00 Mn |
| Mar 31, 2024 | -1.56 Bn |
| Dec 31, 2023 | -2.41 Bn |
| Oct 1, 2023 | 560.00 Mn |
| Jul 2, 2023 | -799.00 Mn |
| Apr 2, 2023 | -1.54 Bn |
| Jan 1, 2023 | 901.00 Mn |
| Apr 3, 2022 | -926.00 Mn |
| Oct 3, 2021 | -1.88 Bn |
| Jul 4, 2021 | 45.00 Mn |
| Apr 4, 2021 | -730.00 Mn |
| Jan 3, 2021 | -903.00 Mn |
| Sep 27, 2020 | 190.00 Mn |